Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 6/20 | 0.63 |
| ▸ | PPARD | Q03181 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | PLAT | P00750 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30084733 | 0.87 | NPC1 (0.65) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL1116290 | 0.87 | NPC1 (0.65) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL5711594 | 0.86 | MAOB (0.74) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL7645821 | 0.86 | MAOB (0.71) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL30231667 | 0.86 | MAOB (0.71) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL539138 | 0.86 | ALDH1A1 (0.55) | MAOBALDH1A1HPGDPPARDKDM4E | |
| SCHEMBL3652542 | 0.86 | MAOB (0.61) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL2010997 | 0.84 | HPGD (0.70) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL11315728 | 0.84 | KLKB1 (0.64) | MAOBALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL10407907 | 0.84 | PLAU (0.58) | MAOBALDH1A1HPGDKDM4EKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | claimed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | claimed |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| EP-4524133-A2 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3939658-B1 | SUBSTITUTED BENZOPYRROLE AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-09-05 | — | — | US | disclosed |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11866418-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| CN-114790159-B | Diphenyl ketone selenoethyl compound and preparation method and application thereof | 合肥学院 | 2023-08-11 | — | — | CN | disclosed |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-5597929-A | Production process of 2-(tetrazol-5-yl)-4-oxo-4H-benzopyran | SUMITOMO CHEMICAL CO., LTD. (JP) | 1997-01-28 | — | — | US | disclosed |
| EP-0716088-A1 | PROCESS FOR PRODUCING 2-(TETRAZOL-5-YL)-4-OXO-4H-BENZOPYRANS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-06-12 | — | — | EP | disclosed |
| EP-0634409-A1 | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-01-18 | — | — | EP | disclosed |
| US-4479007-A | Chroman-4-ones and process for preparing same | BAYER AKTIENGESELLSCHAFT (DE) | 1984-10-23 | — | — | US | disclosed |
| US-4415741-A | REACTING O-HYDROXYACETOPHENONE AND CYCLOPENTANONE | BAYER AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| US-4307020-A | REACTING AN 0-HYDROXYACETOPHENONE WITH A GLYOXYLIC ACID | BAYER AKTIENGESELLSCHAFT (DE) | 1981-12-22 | — | — | US | disclosed |
| US-4285965-A | FUNGICIDES AND INSECTICIDES FOR PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-25 | — | — | US | disclosed |
| EP-0000377-B1 | PROCESS FOR THE PREPARATION OF CHROMONE DERIVATIVES, NEW CHROMONE DERIVATIVES AND THEIR USE AS PLANT-PROTECTING AGENTS | BAYER AG (DE) | 1981-01-21 | — | — | EP | disclosed |
| US-4189498-A | FUNGICIDES, ARTHROPODICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | MAOB 130/4885ALDH1A1 1047/4885CYP3A4 123/4885 |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | MAOB 130/4885ALDH1A1 1047/4885CYP3A4 123/4885 |
| US-11866418-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | MAOB 130/4885ALDH1A1 1047/4885CYP3A4 123/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | MAOB 687/4885ALDH1A1 3179/4885CYP3A4 433/4885 |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | MAOB 130/4885ALDH1A1 1047/4885CYP3A4 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.